Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345774 | 1.00 | MAPT (0.60) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL3881957 | 0.93 | MAPT (0.59) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL21110411 | 0.90 | MAPT (0.60) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL5800651 | 0.89 | MAPT (0.55) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL13430813 | 0.89 | MAPT (0.55) | MAPTSYKKLK7KLK5L3MBTL1 | |
| SCHEMBL8261384 | 0.88 | MAPT (0.54) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL8261840 | 0.88 | MAPT (0.54) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL29458730 | 0.88 | MAPT (0.63) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL5800362 | 0.87 | MAPT (0.57) | MAPTSYKKLK7KLK5FOLH1 | |
| SCHEMBL21109884 | 0.87 | MAPT (0.59) | MAPTSYKKLK7KLK5FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017156071-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8293915-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-1445262-B1 | PEPTIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-7067476-B2 | Peptide derivative, and pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040214780-A1 | Peptide derivative, and pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1445262-A1 | PEPTIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | MAPT 1916/4885SYK 4691/4885KLK7 636/4885 |
| US-20040214780-A1 | Peptide derivative, and pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | ARGLU1, NGLY1, ARG1 | MAPT 4576/4885SYK 249/4885KLK7 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.